

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT POTENTIAL ACCEPTANCE NOTICE OF INVESTIGATIONAL NEW DRUG APPLICATION OF RECOMBINANT ANFIBATIDE INJECTION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that on 25 September 2024, the National Medical Products Administration (the “**NMPA**”) of China has accepted the application for the clinical trial of Recombinant Anfibatide Injection (no.: CXSL2400638, CXSL2400639). This is the first registration application for the clinical trial of the product, and the clinical programme submitted includes Phase I (single dose and multiple doses) and Phase II.

Recombinant Anfibatide Injection is a kind of therapeutic biological product discovered and owned by Zhaoke Pharmaceutical (Hefei) Co. Limited, a wholly-owned subsidiary of the Group, and is in compliance with the good manufacturing practice issued by the NMPA of China.

ABOUT RECOMBINANT ANFIBATIDE

Recombinant Anfibatide is a protein optimised on the basis of the sequence of Agkisacutacin (Antiplatelet Thrombolysin), a natural protein from snake (*Deinagkistrodon acutus*) venom, and expressed in CHO cells as the host cells, and acts on platelet membrane glycoprotein (GPIb). It is a novel drug with a brand-new structure and target. Trials have shown that the drug is an effective GPIb inhibitor for GPIb-vWF interaction by binding to GPIb α , a target that is effective in inhibiting thrombosis, preventing myocardial infarction and thrombotic thrombocytopenic purpura. The Group owns the global intellectual property rights of this drug.

* For identification purpose only

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with 30 years' experience in the pharmaceutical industry in China. With solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales, and marketing, the Company has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau, and Taiwan. Lee's Pharm focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics and other fields, with products in different development stages. Over the past two years, Lee's Pharm has successfully obtained 13 new drug approvals in China. More information is available at www.leespharm.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 14 October 2024

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie Chin are non-executive Directors; Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl, are independent non-executive Directors.